Navigation Links
A classic method for modeling skin cancer is featured in Cold Spring Harbor Protocols
Date:9/4/2007

COLD SPRING HARBOR, N.Y. (Tues., Sept. 4, 2007) Skin cancer is the most prevalent form of human cancer in the United States, according to the Centers for Disease Control. But in order to more fully understand skin cancer in humans, scientists must use model organisms, such as mice, to study the disease in the laboratory.

This months release of Cold Spring Harbor Protocols (www.cshprotocols.org) includes free access to a protocol for generating mice with squamous cell carcinoma (SCC), one of the most common types of skin cancer. The procedure involves injecting mice with a drug called DMBA, which mutates (and thereby activates) a tumor-promoting gene. A second drug, called TPA, then encourages the proliferation of cells that carry the mutated gene. The resulting mass of cells is a tumor.

The protocol, freely available at http://www.cshprotocols.org/cgi/content/full/2007/18/pdb.prot4837, describes how to monitor and evaluate the mice for clinical signs of tumorigenesis. It also includes methods for preparing the tumor tissues for histological analysis, which allows scientists to study characteristics of the tumors at a microscopic level.

The protocol is from Dr. Michael Girardis group at the Yale University School of Medicine (http://info.med.yale.edu/dermatology/dept/girardi.html). Girardis team has used the procedure to examine the role of the immune system in susceptibility to SCC. It can also be used to test other physiological and environmental factors that may influence the growth and progression of skin cancer in mice, and will ultimately help scientists to better understand and control the disease in humans.

Also freely available from Cold Spring Harbor Protocols this month is an article that describes an efficient method for testing individuals for specific DNA variations called SNPs (single-nucleotide polymorphisms) (http://www.cshprotocols.org/cgi/content/full/2007/18/pdb.prot4843). The method, called the oligonucleotide ligation assay (OLA), will be useful for identifying individuals with disease-related mutations and other genetic variants. It was contributed by Dr. Stuart Macdonald from the University of Kansas (http://web.ku.edu/sjmac/).


'/>"/>

Contact: Maria Smit
smit@cshl.edu
516-422-4127
Cold Spring Harbor Laboratory
Source:Eurekalert

Related medicine news :

1. Ultrasound may mean end to classic stethoscope
2. New methods to prevent injury of patients
3. A new method to help smokers quit
4. Methods to have a flat stomach
5. Bioengineering production strains - Microbia develops new methods
6. New method of measuring arterial stiffness in elderly hypertensives
7. Easier Methods Required to Screen Insulin Resistance
8. Easier Methods Required to Screen Insulin Resistance
9. Accuracy of Some Natural Family Planning Methods Questioned .
10. New Method Of Delivering Chemotherapy
11. Adopting Easier Methods To Screen Insulin Resistance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... ... Global Healthcare Management’s 4th Annual Kids Fun Run brought out many kids this ... by Global Healthcare Management’s CEO, Jon Letko, is aimed at getting kids excited about ... ages; it is a non-competitive, non-timed event, which is all about having fun and ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... “The Journey: ... faced every danger possible to save lost souls in the Philippines. “The Journey: From ... Carole is a dedicated teacher of the Bible. She has taught all ages and ...
(Date:10/12/2017)... ... 2017 , ... Planet Fitness, one of the largest and fastest growing franchisors ... a flagship location in Covington, LA at 401 N. U.S. Highway 190, in January ... Office Depot in the Holiday Square shopping center. Its location allows it to serve ...
(Date:10/12/2017)... ... October 12, 2017 , ... Asante, a ... health care, have expanded their existing home health joint venture through an agreement, ... been operating a joint venture home health company with Asante, delivering clinically integrated ...
(Date:10/12/2017)... ... 12, 2017 , ... Leading pediatric oncology experts at Children’s National Health ... Congress of the International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired ... Cancer and Blood Disorders at Children’s National, and Stephen P. Hunger, M.D., Chief ...
Breaking Medicine News(10 mins):
(Date:9/25/2017)... 25, 2017  EpiVax, Inc., a leader in ... immune-engineering today announced the launch of EpiVax Oncology ... personalized therapeutic cancer vaccines. EpiVax has provided $500,000 ... to enabling technologies to the new precision immunotherapy ... EpiVax Oncology as Chief Executive Officer. Gad brings ...
(Date:9/19/2017)... Sept. 19, 2017   ZirMed Inc ., a recognized ... announced that it has been ranked #1 by its users ... Rankings 2017 User Survey. ZirMed was recognized as the ... hospitals and medical centers over 200 beds and holds one ... technology user survey history. ...
(Date:9/12/2017)... reviews on the independent review site Consumer Affairs have ... hearing aids, ranking it higher than Miracle Ear ™, Beltone™, ... ... Aids ... that provides high performance, state-of-the-art, German-engineered hearing aids directly to consumers ...
Breaking Medicine Technology: